个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ ESCI

作者：
Renal Cancer Quality Control Experts Committee of National Cancer Quality Control Center[1] ; National Cancer Center of the People’s Republic of China[1] ; Yao Lin[1] ; Du Yicong[1] ; Dong Wen[2] ; Gao Xianshu[3] ; Guo Jun[4] ; Qiu Jianxing[5] ; Wei Qiang[6] ; Wu Shikai[7] ; Ye Dingwei[8] ; Yu Wei[1] ; Zeng Hao[6] ; Zhang Qian[1] ; Zhang Yong[9] ; Zhang Zhiling[10] ; Zhou Fangjian[10] ; Yang Wenjing[11] ; Wang Hui[11] ; Zhang Xu[12] ; He Zhisong[1] ;
机构： [1]Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China. [2]Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. [3]Department of Radiation Oncology, Peking University First Hospital, Beijing, China. [4]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. [5]Department of Radiology, Peking University First Hospital, Beijing, China. [6]Department of Urology, West China Hospital, Sichuan University, Chengdu, China. [7]Department of Oncology, Peking University First Hospital, Beijing, China. [8]Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. [9]Department of Urology Surgery, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [10]Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China. [11]Office for Cancer Diagnosis and Treatment Quality Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [12]Department of Urology, The Third Medical Center, Chinese People Liberation Army (PLA) General Hospital, Beijing, China.
出处：
DOI： 10.1016/j.jncc.2023.11.004

关键词： Renal cancer Standardized diagnosis and treatment Quality control index

摘要：
Renal cancer is one of the most common malignancies of the urinary system, and the number of deaths continues to increase. The standardized management of the diagnosis and treatment of renal cancer is challenging due to the great differences in the diagnosis and treatment of renal cancer in different regions. The Renal Cancer Expert Committee of the National Cancer Quality Control Center (NCQCC) identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of renal cancer. The Renal Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization, uniformity, and normalization of renal cancer diagnosis and treatment, which ultimately improved the survival rate and quality of life of renal cancer patients. A panel of experts with renal cancer surgery, renal cancer medicine, medical imaging, pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of renal cancer. The Indices includes 20 items that cover all key areas in the diagnosis and treatment of renal cancer, such as standard diagnosis, surgery treatment, systemic treatment, and prognostic evaluation.© 2023 Chinese National Cancer Center. Published by Elsevier B.V.

基金：
Peking University First Hospital Domestic Multicenter Clinical Research Special Fund-Central High Level Hosptal Clinical Research Business Fund (grant number: 2022CR54), Peking University Medical Innovation Translation Special Fund (grant number: 2022FY03), Peking University First Hospital Scientific and Technological Achievement Transformation Incubation Guidance Fund (grant number: 2022CX02), 2020 Capital Health Development Research Special Project (grant number: 2020-2Z-40713), and National Key Research and Development Program Scheme (grant number: 2023YFC2415500).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2024]版：
Q1 ONCOLOGY
最新[2024]版：
Q1 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Renal Cancer Quality Control Experts Committee of National Cancer Quality Control Center,National Cancer Center of the People’s Republic of China,Yao Lin,et al.Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)[J].Journal Of The National Cancer Center.2024,4(1):6-13.doi:10.1016/j.jncc.2023.11.004.
APA：
Renal Cancer Quality Control Experts Committee of National Cancer Quality Control Center,National Cancer Center of the People’s Republic of China,Yao Lin,Du Yicong,Dong Wen...&He Zhisong.(2024).Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition).Journal Of The National Cancer Center,4,(1)
MLA：
Renal Cancer Quality Control Experts Committee of National Cancer Quality Control Center,et al."Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)".Journal Of The National Cancer Center 4..1(2024):6-13

相关文献

[1]Renal pelvic metastasis from non-small cell lung cancer with renal vein thrombosis. [2]Genomic alterations and diagnosis of renal cancer [3]Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma. [4]Case report: Synchronous prostate cancer and renal cell carcinoma with prostate cancer-origin metastases to adrenal and renal hilar lymph nodes [5]Higher genetically predicted low-density lipoprotein levels increase the renal cancer risk independent of triglycerides and high-density lipoprotein levels: a Mendelian randomization study. [6]Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma. [7]OIP5基因在肾癌中的表达及作用 [8]Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk [9]Effect of tumor size on cancer-specific survival in small T1 renal cell carcinoma [10]Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma

资源点击量：65780 今日访问量：0 总访问量：5151 更新日期：2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号